We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fluorescence-Based Assay for Alzheimer's Research

By Biotechdaily staff writers
Posted on 07 Oct 2003
A new fluorescence-based assay utilizes a super-quenching polymer that offers greater sensitivity and specificity for high-throughput screening and drug discovery related to Alzheimer's disease.

A technique commonly used in screening new drug candidates is fluorescence resonance energy transfer (FRET), The new assay offers several advantages over conventional FRET. More...
Typically, FRET reactions couple a single fluorophore with a single quencher molecule. The new assay couples a quencher molecule with a fluorescent polymer chain. Each quencher alters fluorescence of several hundred fluorophores. This enhanced activity provides not only greater sensitivity and specificity but also takes less time for results and reduces costs.

The assay, called QTL Lightspeed Beta-Secretase Assay Kit, combines high sensitivity with high speed for screening potential inhibitors against beta-secretase. The major constituent of the senile plaques associated with Alzheimer's disease is the beta-amyloid peptide, generated by the activity of the enzyme beta-secretase in the brain. The assay is the product of QTL Biosystems, LLC (Santa Fe, NM, USA).

"Because the QTL Lightspeed Beta-Secretase Assay Kit generates a large signal, researchers will be able to generate results that offer better signal-to-noise ratio, more robustness, enhanced sensitivity, and quicker time to results, even at the highest throughput densities,” said Dunan McBranch, Ph.D., CEO of QTL Biosystems.




Related Links:
QTL Biosystems

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.